Category
Europe
Health technology assessment, pricing and access across Europe, including EU-level joint clinical assessment and the national systems that still decide funding. Coverage spans the major markets and the smaller systems that often move first.
723 articles in this topic.
Articles in this category

11/18/2026
EU Medical Device Reform Only Partly Fixes Rules for AI-Enabled Medical Devices
Authors writing in npj Digital Medicine say the EU MDR reform eases some burdens for AI-enabled medical devices but leaves adaptive and agentic AI unresolved. #SyenzaNews #MarketAccess
Read Article →
11/18/2026
FDA Launches Global Reliance Disclosure Program for Approval Packages
The FDA's Global Reliance Disclosure Program lets companies pass minimally redacted approval packages to regulators outside the US. Lenacapavir is the launch case, and the FDA intends to widen the program in January 2027. #SyenzaNews #MarketAccess
Read Article →
11/17/2026
Povorcitinib for Hidradenitis Suppurativa: CHMP Recommends Povofortay
The CHMP has recommended povorcitinib for hidradenitis suppurativa as Povofortay, a JAK1 inhibitor for adults who responded inadequately to, or are intolerant or contraindicated to, anti-TNF therapy.
Read Article →
11/17/2026
EMA Recommends Gazyvaro for Systemic Lupus Erythematosus: What the Trial Shows
EMA recommends Gazyvaro for systemic lupus erythematosus after a 303-patient trial showed 76.7% response on add-on therapy versus 53.5% on placebo.
Read Article →
11/16/2026
NICE Draft Guidance Backs Capsule Sponge Tests for Oesophageal Cancer
NICE draft guidance recommends Cytosponge and EndoSign to help detect oesophageal cancer and Barrett's oesophagus. The tests need no sedation and can be done outside hospital. #SyenzaNews #MarketAccess #HealthTech
Read Article →
11/16/2026
CHMP November 2026 Recommends Seven New Medicines for Approval
EMA's CHMP recommended seven new medicines and 11 indication extensions at its 9 to 12 November 2026 meeting, and confirmed two refusals after re-examination.
Read Article →
11/16/2026
Baxfendy EU Positive Opinion: CHMP Backs AstraZeneca’s Hypertension Tablet
The CHMP recommended granting a marketing authorisation for AstraZeneca's Baxfendy (baxdrostat) for insufficiently controlled hypertension. The European Commission makes the final decision. #SyenzaNews #MarketAccess
Read Article →
11/13/2026
Appropriate Comparator Use for EMA-Approved Drugs Fell From 2011 to 2024
Only 58% of EMA-approved drug indications from 2011 to 2024 had at least one trial population tested against an appropriate comparator. The share fell from 78% of 2011 to 2012 approvals to 39% of 2023 to 2024 approvals. #SyenzaNews #MarketAccess
Read Article →
11/12/2026
US MFN Drug Pricing: A 25% German Price Rise Would Cut Medicaid Savings by 3.8%
A preprint led by Thomas Hwang models how German price changes affect US Medicaid MFN savings and German statutory health insurance spending.
Read Article →
11/12/2026
The EU HTA Regulation: What Latin America Can Learn
A PAHO, RedETSA and HTAi webinar on the EU HTA Regulation: what Latin American agencies can reuse from joint clinical assessments, and which elements may be hard to adapt.
Read Article →
11/12/2026
Artificial Intelligence in Medicine Regulation: From Concept to Practice
EMA says it is moving artificial intelligence in medicine regulation from concept to practice. Its timeline runs from a 2021 joint workshop to research priorities published in August 2026. #SyenzaNews #MarketAccess #drugregulation
Read Article →
11/12/2026
EMA Draft Guideline on Predictive Biomarker Assays Opens Public Consultation to 31 March 2027
The European Medicines Agency has opened public consultation on its draft guideline on predictive biomarker assays. Comments are accepted from 9 November 2026 until 31 March 2027.
Read Article →


